Aviceda Therapeutics to wind down after Phase 2 failure in geographic atrophy program

Aviceda Therapeutics, a biotech focused on geographic atrophy, announced it is winding down operations.

The decision follows a Phase 2 trial that did not meet its endpoints, halting plans to move the eye drug candidate into Phase 3 later this year.

The shutdown underscores the challenges of developing treatments for geographic atrophy, a leading cause of vision loss, and may affect investors and partners tracking the space.